Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751788 | 0.72 | PIK3CG (0.38) | — | |
| SCHEMBL11615247 | 0.67 | CYP2A6 (0.32) | MTOR | |
| SCHEMBL12825489 | 0.67 | — | — | |
| SCHEMBL28865029 | 0.67 | PDE4A (0.34) | — | |
| SCHEMBL862484 | 0.65 | — | — | |
| SCHEMBL6338653 | 0.65 | — | — | |
| SCHEMBL6719246 | 0.64 | PIK3CG (0.33) | — | |
| SCHEMBL24122008 | 0.63 | CHRM4 (0.36) | — | |
| SCHEMBL12506114 | 0.61 | — | — | |
| SCHEMBL30592426 | 0.61 | MAPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142555-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009037168-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009013171-A2 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | PIK3CA 1159/4885MTOR 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.